TCT 2019 News: HeartFlow Planner and Cost-effectiveness Analysis

This year’s Transcatheter Cardiovascular Therapeutics (TCT) conference was terrific, as it gave me a chance to learn the latest structural heart and PCI data, and reconnect with friends and colleagues. As the Chief Medical Officer of a company that provides a technology that combines anatomy and physiology, I was encouraged that throughout the week at TCT, there was a strong emphasis on how anatomy and physiology provide different, complementary, and equally important pieces of information to help practitioners optimize treatment for patients.

There were also a couple of exciting HeartFlow updates at TCT. The first was a cost-effectiveness analysis of HeartFlow, which was presented by Dr. Udo Hoffmann of Massachusetts General Hospital. The objective was to compare the cost-effectiveness of three alternative non-invasive testing strategies (non-invasive functional testing, coronary CTA alone or coronary CTA + HeartFlow when indicated) in patients with stable chest pain. For the analysis, Hoffmann and his team applied Markov modeling, a well-established probabilistic method, on 10,003 patients from the PROMISE trial. Using this technique, the key findings were that a coronary CTA + HeartFlow testing pathway resulted in:

Read More

The second HeartFlow update at TCT was the introduction of HeartFlow Planner, a non-invasive, realtime planning tool that enables interventional cardiologists to model vessels virtually, and to preview different treatment strategies. HeartFlow Planner is now FDA cleared, and we are currently working with a few sites on beta evaluation to understand how it fits best into pre- and intra-procedural workflows. During TCT, we were able to gather feedback from clinicians on how they might envision using HeartFlow Planner in their practices. The feedback overall has been encouraging and we look forward to making Planner more broadly available in 2020.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.